BSGM实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	105 648
平均成交量	1.22M
市值	19.15M
EPS	$0 ( 2024-03-29 )
下一个收益日期	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.430
ATR14	$0.0220 (1.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Hrkac Frederick	Buy	500 000	Common Stock
2023-12-28	Hrkac Frederick	Buy	900 000	Restricted Stock Units
2023-12-28	Hrkac Frederick	Buy	600 000	Stock Option (Right to Buy)
2023-11-30	Sieckhaus John	Buy	92 300	Common Stock
2023-11-30	Fleming Gray	Buy	131 900	Common Stock

INSIDER POWER
100.00
Last 95 transactions
Buy: 6 442 688 \| Sell: 40 000

音量相关性

長: -0.11 (neutral)

短: -0.72 (moderate negative)

Signal:(55.608) Neutral

Biosig Technologies Inc 相关性

10 最正相关
ROIV	0.951
RDFN	0.939
CRNC	0.935
NLSP	0.934
KSPN	0.934
ALGN	0.932
VRM	0.931
PLL	0.927
EVCM	0.927
IMV	0.926

10 最负相关
GRIN	-0.94
HQY	-0.936
TIL	-0.933
MTEX	-0.924
RIVN	-0.922
ROVR	-0.922
GBNY	-0.919
ZENV	-0.919
PIII	-0.916
AVIR	-0.916

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Biosig Technologies Inc 相关性 - 货币/商品

0.72
( moderate )

0.03
( neutral )

0.00
( neutral )

0.14
( neutral )

0.66
( moderate )

-0.63
( weak negative )

Biosig Technologies Inc 财务报表

Annual	2023
营收:	$18 000.00
毛利润:	$-343 000 (-1 905.56 %)
EPS:	$-3.95

FY	2023
营收:	$18 000.00
毛利润:	$-343 000 (-1 905.56 %)
EPS:	$-3.95

FY	2022
营收:	$286 000
毛利润:	$229 000 (80.07 %)
EPS:	$-6.40

FY	2021
营收:	$441 000
毛利润:	$242 000 (54.88 %)
EPS:	$-0.950

Financial Reports:

No articles found.

Biosig Technologies Inc

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.